Australia’s bad drug deal

by Stephen Duckett

Australia’s Pharmaceutical Benefits Scheme pays at least $1.3 billion a year too much for prescription drugs. New Zealand, which has capped its budget and appointed independent experts to make decisions, pays a sixth as much as the PBS for the same drugs. This report proposes three ways Australia can regain its lost leadership in pharmaceutical pricing.

Watch an interview with Stephen Duckett

A free public lecture in Canberra hosted by ANU, Stephen Duckett discussed the report findings.

Read Stephen Duckett’s article in The Conversation

Stephen Duckett talks to ABC Health Report presenter Norman Swan about why pharmaceutical prices are too high and what should be done.

He also talks about his report with Amanda Vanstone, presenter of the ABC’s Counterpoint.

Download Report

Download Media Release

Download Stephen Duckett's ANU presentationn

Related Articles


07 March 2017

Time to slay a pharmaceutical zombie

Published by Inside Story, Tuesday 7 March Among the 2014 federal budget’s “zombie” measures still languishing in parliamentary limbo is a proposal to increase Medicare co-payments and loose…


05 March 2017

Cutting a better drug deal

Australians pay more than $500 million a year too much for their prescription drugs. Taxpayers and patients would pay less if the Federal Government made some simple changes to the way prices are s…


31 March 2017

Different drugs, same benefits

Published by Inside Story, Friday 31 March On 1 April a series of new drugs will be added to the Pharmaceutical Benefits Scheme, or PBS, and prices for some old drugs drop. But the news could and s…